KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:待检查

Ultra-high dose radiation for Liver metastasis using MR-guided TReatment with stereotactic Ablative Single-fraction (ULTRAS): study protocol for a phase III randomized controlled trial.

Harroun Wong, Sylvia S W Ng, Issa Mohamad, Jooya Alborz, Teodor Stanescu, Zhihui Amy Liu, Jeremy De Leon, Hendrick Tan, Sweet Ping Ng, Ganesh Radhakrishna, Rana Bahij, Martijn Intven, Alexander Kirichenko, Aruz Mesci, Michael Yan, Laura Dawson, Todd Augilera, Ali Hosni

Contemp Clin Trials 167 108381

PMID42309387
PMCID-
DOI10.1016/j.cct.2026.108381
发表日期2026-06-17
AI 判定为临床试验方案/Protocol,尚非正式结果论文;因此未进入 KM Figure 抓取。
摘要

摘要

INTRODUCTION: Liver metastases are common in several malignancies, with only 15-20% of patients eligible for surgical resection. For non-surgical candidates, stereotactic body radiation therapy (SBRT) is an effective alternative with acceptable local control (LC) rates. Higher biologically effective doses (BED10 > 100 Gy10) are associated with improved LC, and single-fraction ultra-high dose SBRT (35-40 Gy) has demonstrated excellent LC with minimal toxicity. MR-guided adaptive SBRT enhances precision and may optimizing single-fraction SBRT for liver metastases. METHODS AND ANALYSIS: ULTRAS is a multi-center, phase III randomized trial evaluating whether ultra-high dose MR-guided single-fraction SBRT (38 Gy, BED10 ≈ 180 Gy10) improves LC of liver oligometastases/oligoprogression compared to high-dose MR-guided single-fraction SBRT (27 Gy, BED10 ≈ 100 Gy10). Primary endpoint is LC of treated intrahepatic target lesion(s). Secondary endpoints include overall survival (OS), progression-free survival (PFS), intrahepatic and extrahepatic progression, toxicity (CTCAE v5.0 and PRO-CTCAE v1.0), and quality of life (QOL) (EORTC QLQ-C15-PAL, EORTC QLQ-LM21). Patients will be randomized 1:1 to receive either 27 Gy or 38 Gy, stratified by primary tumor site/histology, lesion characteristics, and prior systemic therapy. A total of 114 patients (57 per arm) will be enrolled over three years, with two years of follow-up. Assessments at predefined intervals will monitor response and toxicity. LC will be analyzed using cumulative incidence function. Widespread and intrahepatic progression will be assessed using Fine & Gray regression; OS and PFS via Cox models; toxicity and QOL via Chi-squared test and mixed-effects model. ETHICS AND DISSEMINATION: The ULTRAS trial obtained ethical approval from the University Health Network and will follow ICMJE reporting standards. TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT06362395.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。